Name of Patient (in alphabetical order)	Diagnosis	Date Entered IND Program	Marijuana Dosage Per Month (One cured ounce is about 40 cigarettes)	Status (as of Apr. 18, 2014)
1. Douglass, Barbara	Multiple Sclerosis	Aug. 30, 1991	Nine cured oz (360 joints)	Active program participant
2. Jenks, Barbra	AIDS	Feb. 19, 1991 (1st shipment)	Unknown	Passed away Mar. 28, 1992
3. Jenks, Kenny	AIDS	Feb. 19, 1991 (1st shipment)	Unknown	Passed away July 19, 1993
4. McMahon, George	Nail Patella Syndrome	Mar. 16, 1990	Eight cured oz (320 joints)	Active program participant
5. Millet, Corrine	Glaucoma	Nov. 16, 1990	Four cured oz (160 joints)	Passed away Dec. 2007
6. Musikka, Elvy	Glaucoma	Oct. 17, 1988	Eight cured oz (320 joints)	Active program participant
7. Randall, Robert	Glaucoma	Nov. 1976	Unknown	Passed away June 2, 2001
8. Rosenfeld, Irvin	Multiple Congenital Cartilaginous Exostoses	Nov. 20, 1982	Nine cured oz (360 joints)	Active program participant

*There were also two anonymous patients in the program whose names were witheld by request. These two patients are thought to have passed away based on evidence presented below, although their status cannot be confirmed due to their anonymity.

[Editor’s note: ProCon.org contacted the National Institute on Drug Abuse (NIDA) – the government organization that has supplied marijuana for the Compassionate Use IND program since it began on May 10, 1978 – several times in Mar. and Apr. 2008 to verify the status and number of patients in the program. On May 10, 2008 we received an email from NIDA Press Chief Dorie Hightower stating:

“NIDA is not in charge of this program in any way. All we do is ship mj [marijuana] to appropriately registered physicians on behalf of their patients. We have no way of knowing how many are actively receiving mj.”

ProCon.org called or emailed the US Food and Drug Administration (FDA) – the government organization that approves all IND programs – on May 12, 13, 14, 21, 28 and 29, 2008. We received an email from FDA spokeswoman Rita Chappelle on May 21, 2008 informing us they would not answer our requests for information and instructing us to call their consumer line, which we did. Katherine Chew returned our message and further declined to provide any information about the FDA’s involvement in this program. A follow up email from ProCon.org to the FDA ombudsman and drug information email address was answered on June 3, 2008 by FDA spokeswoman Crystal Rice:

“I regret that you’ve been faced with some difficulties in communicating with and receiving information from our agency. However, I must reiterate the statement made by one of my colleagues that any investigational new drug application information is proprietary and must come from the sponsor.

In regard to ‘medical’ marijuana, in general, here is our most recent agency statement: Inter-Agency Advisory Regarding Claims That Smoked Marijuana Is a Medicine.”

Read more about this federal program in our question: “What is the US government’s Compassionate Investigational New Drug (IND) program for medical marijuana?”

See videos of some of the patients on our YouTube playlist “Medical Marijuana: IND Patients.”]